Pacritinib

CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19

Retrieved on: 
Monday, April 27, 2020
Medicine, Clinical medicine, Ethers, Pacritinib, Pyrrolidines, Thrombocytopenia, Branches of biology

SEATTLE, April 27, 2020 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19.

Key Points: 
  • SEATTLE, April 27, 2020 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19.
  • PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, will compare pacritinib plus standard of care (SOC) versus placebo plus standard of care in 358 hospitalized patients with severe COVID-19, including patients withand withoutcancer.
  • With ample supply of pacritinib available, we continue to recruit patients on the pivotal Phase 3 PACIFICA trial of pacrtitnib in myelofibrosis patients with severe thrombocytopenia."
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

Retrieved on: 
Tuesday, October 1, 2019
Clinical medicine, Medicine, Pyrrolidines, Ethers, Pacritinib, Myelofibrosis, Thrombocytopenia, Branches of biology

SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment candidate, pacritinib.

Key Points: 
  • SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment candidate, pacritinib.
  • Moving forward, successful trial execution is our primary focus, and with patient enrollment now underway, we expect to report topline results in mid-2021."
  • The PACIFICA trial is a randomized, active-comparator trial designed toevaluate the safety and efficacy of 200 mg of pacritinib administered twice daily (BID) compared to Physician's Choice in 180 myelofibrosis patients with severe thrombocytopenia (platelet counts of less than 50,000 per microliter).
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis

Retrieved on: 
Thursday, July 18, 2019
Pyrrolidines, Ethers, Pacritinib, Myelofibrosis, Cancer, Clinical medicine, Chemistry, Pyrimidines

Following this meeting, CTI plans to evaluate 200 mg of pacritinib administered twice daily (BID) in 180 patients with myelofibrosis and severe thrombocytopenia.

Key Points: 
  • Following this meeting, CTI plans to evaluate 200 mg of pacritinib administered twice daily (BID) in 180 patients with myelofibrosis and severe thrombocytopenia.
  • The randomized, open-label Phase 2 PAC203 dose-finding study was designed to evaluate the safety and efficacy of three dosing regimens of oral pacritinib in 150 patients with myelofibrosis.
  • CTI BioPharma Corp. is a biopharmaceutical company focused on the development and commercialization of pacritinib for the treatment of adult patients with myelofibrosis.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20

Retrieved on: 
Thursday, June 13, 2019
Ethers, Pacritinib, Pyrrolidines, Life sciences, Chemistry, Natural sciences

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers.

Key Points: 
  • CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers.
  • The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of adult patients with myelofibrosis.
  • CTI BioPharma is headquartered in Seattle, Washington.

CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5

Retrieved on: 
Wednesday, May 29, 2019
Ethers, Pacritinib, Pyrrolidines, Life sciences, Chemistry, Natural sciences

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers.

Key Points: 
  • CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers.
  • The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of adult patients with myelofibrosis.
  • CTI BioPharma is headquartered in Seattle, Washington.

CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10

Retrieved on: 
Wednesday, April 3, 2019
Ethers, Pacritinib, Pyrrolidines

SEATTLE, April 3, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central.

Key Points: 
  • SEATTLE, April 3, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central.
  • CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
  • The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of patients with myelofibrosis.
  • CTI BioPharma is headquartered in Seattle, Washington.

CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

Retrieved on: 
Wednesday, March 13, 2019
Ethers, Pacritinib, Pyrrolidines, Chemistry

SEATTLE, March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018.

Key Points: 
  • SEATTLE, March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018.
  • The Company further expects to report topline efficacy and safety data from the Phase 2 study by the end of 2019."
  • The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of patients with myelofibrosis.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27

Retrieved on: 
Wednesday, February 20, 2019
Leerink Partners, Pacritinib

SEATTLE, Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel.

Key Points: 
  • SEATTLE, Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel.
  • CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
  • The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of patients with myelofibrosis.
  • CTI BioPharma is headquartered in Seattle, Washington.

CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018

Retrieved on: 
Thursday, October 25, 2018
Ethers, Pacritinib, Pyrrolidines

SEATTLE, Oct. 25, 2018 /PRNewswire/ --CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results onThursday, November 1, 2018, after the close of the U.S. financial markets.

Key Points: 
  • SEATTLE, Oct. 25, 2018 /PRNewswire/ --CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results onThursday, November 1, 2018, after the close of the U.S. financial markets.
  • Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at4:30 p.m.
  • Access to the event can be obtained as follows:
    To access the live audio webcast or the subsequent archived recording, visit CTI BioPharma's website, www.ctibiopharma.com .
  • The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of patients with myelofibrosis.

CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

Retrieved on: 
Wednesday, September 26, 2018
Ethers, Pacritinib, Pyrrolidines, Chemistry, Clinical medicine

SEATTLE, Sept. 26, 2018 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel.

Key Points: 
  • SEATTLE, Sept. 26, 2018 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel.
  • CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
  • CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis.
  • CTI BioPharma is headquartered in Seattle, Washington.